CurveBeam AI Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

CurveBeam AI (ASX:CVB) Full Year 2024 Results

Key Financial Results

• Revenue: AU$6.53m (down 19% from FY 2023).
• Net loss: AU$23.1m (loss narrowed by 55% from FY 2023).
• AU$0.081 loss per share (improved from AU$0.88 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

CurveBeam AI EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 42%. Earnings per share (EPS) exceeded analyst estimates by 81%.

Looking ahead, revenue is forecast to grow 49% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia.

Performance of the Australian Medical Equipment industry.

The company's shares are down 5.4% from a week ago.

Risk Analysis

You should learn about the 4 warning signs we've spotted with CurveBeam AI.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.